1.
两组患者一般资料的比较
The base-line characteristics of the groups
| Characteristics | G-T group (n=49) | T-G group (n=56) | P |
| G-T group: patients receiving gemcitabine +/- platinum first-line followed by taxanes +/- platinum second-line; T-G group: patients receiving taxanes +/- platinum first-line followed by gemcitabine +/- platinum second-line. ECOG PS: Eastern Cooperative Oncology Group Performance Status. | |||
| Gender | 0.740 | ||
| Male | 39 (79.6%) | 46 (82.1%) | |
| Female | 10 (20.4%) | 10 (17.9%) | |
| Age (yr) | 0.647 | ||
| Median (range) | 62 (39-78) | 59 (37-83) | |
| Smoking status | 0.521 | ||
| Ever-smoker | 34 (69.4%) | 42 (75.0%) | |
| Never-smoker | 15 (30.6%) | 14 (25.0%) | |
| Disease stage | 0.425 | ||
| Ⅲb | 6 (12.2%) | 10 (17.9%) | |
| Ⅳ | 43 (87.8%) | 46 (82.1%) | |
| ECOG PS | 0.206 | ||
| 0 | 0 (0) | 2 (3.6%) | |
| 1 | 46 (93.9%) | 47 (83.9%) | |
| 2 | 3 (6.1%) | 7 (12.5%) | |
| Thoracic radiotherapy | 0.353 | ||
| Performed | 15 (30.6%) | 22 (39.3%) | |
| Not performed | 34 (69.4%) | 34 (60.7%) | |
| Combined with platinum | 0.554 | ||
| G (T)+platinum-T (G)+platinuem | 28 (57.1%) | 36 (64.3%) | |
| G (T)+platinum-G (T) | 16 (32.7%) | 13 (23.2%) | |
| G (T)-T (G) | 5 (10.2%) | 7 (12.5%) | |
| First-line platinum drugs | 0.440 | ||
| Carboplatin | 16 (32.7%) | 24 (42.9%) | |
| Cisplatin | 28 (57.1%) | 25 (44.6%) | |
| Single agent | 5 (10.2%) | 7 (12.5%) | |
| Second-line platinum drugs | 0.648 | ||
| Carboplatin | 19 (38.8%) | 22 (39.3%) | |
| Cisplatin | 9 (18.4%) | 14 (25.0%) | |
| Single agent | 21 (42.9%) | 20 (35.7%) | |
| Taxanes drugs | 0.582 | ||
| Docetaxel | 28 (57.1%) | 29 (51.8%) | |
| Paclitaxel | 21 (42.9%) | 27 (48.2%) | |